Product Description
Etonogestrel implant is used in women to prevent pregnancy. It is a form of birth control that contains a hormone in a flexible plastic rod about the size of a matchstick. It is effective for 3 years when inserted just beneath the skin of your upper arm. This medicine stops the release of an egg from your ovary. The mucus in your cervix thickens and may prevent sperm from reaching the egg. (Sourced from: https://www.mayoclinic.org/drugs-supplements/etonogestrel-intradermal-route/side-effects/drg-20069037?p=1)
Mechanisms of Action: ER Agonist, PR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Vaginal, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Hungary | Iceland | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Organon
Company Location: JERSEY CITY NJ 07302
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Puerto Rico, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Contraception
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04626596 |
MK-8415-060 | P3 |
Completed |
Contraception |
2024-12-30 |
41% |
2025-01-14 |
|
NCT05994599 |
EVE-P6-604 | P1 |
Completed |
Contraception |
2023-12-11 |
2024-07-23 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/10/2025 |
News Article |
Organon Reports Results for the Third Quarter Ended September 30, 2025 |
|
10/27/2025 |
News Article |
Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation |
|
09/22/2025 |
News Article |
Global Office Sleep Pod Market Expected to Surge to USD 550 Million by 2033, Growing at a Robust CAGR of 12.5% from 2026 to 2033 - Market Research Intellect |
|
08/05/2025 |
News Article |
Organon Reports Results for the Second Quarter Ended June 30, 2025 |